TNF and inflammatory bowel disease: The makeup of the patient cohort was as follows: 13 (33.3%) with moderate-to-severe IBD starting anti-TNF therapy (of which 6 had UC), 25 (64.1%) beginning Vedolizumab treatment (with 13 having UC) and 1 (2.6%) with CD starting Ustekinumab therapy.